20:16 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

AADvac1: Ph I data

A double-blind, placebo-controlled, Austrian Phase I trial in 30 patients ages 50-85 with mild to moderate AD showed that once-monthly subcutaneous AADvac1 for 3 months led to an IgG immune response in 29 patients. The...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

AADvac1: Phase II started

Axon Neuroscience began the double-blind, placebo-controlled, European Phase II ADAMANT trial to evaluate subcutaneous AADvac1 given monthly for 6 months followed by 2 booster doses given in 6-month intervals in about 185 patients. Axon Neuroscience...